Dashboard
Manage Tickers

PRQRProQR Therapeutics N.V.

Nasdaq proqr.com


$ 1.70 $ 0.06 (3.66 %)    

Friday, 05-Jul-2024 15:09:06 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 495.80 $ 5.12 (1.04 %)
DIA $ 393.71 $ 0.87 (0.22 %)
SPY $ 554.29 $ 3.18 (0.58 %)
TLT $ 92.56 $ 0.76 (0.83 %)
GLD $ 220.89 $ 2.94 (1.35 %)
$ 1.7
$ 1.66
$ 0.00 x 0
$ 1.72 x 300
$ 1.66 - $ 1.70
$ 1.11 - $ 3.29
146,864
na
138.3M
$ 1.05
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

proqr-presents-its-axiomer-rna-editing-technology-at-rna-editing-summit
ProQR Presents Its Axiomer RNA Editing Tec...
06/18/2024 12:20:41

ProQR Therapeutics NV (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today ...

chardan-capital-maintains-buy-on-proqr-therapeutics-maintains-25-price-target
Chardan Capital Maintains Buy on ProQR The...
05/10/2024 14:14:00

Chardan Capital analyst Keay Nakae maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and maintains $2.5 price target.

hc-wainwright--co-reiterates-buy-on-proqr-therapeutics-maintains-5-price-target
HC Wainwright & Co. Reiterates Buy on ProQ...
05/10/2024 12:21:51

HC Wainwright & Co. analyst Andrew Fein reiterates ProQR Therapeutics (NASDAQ:PRQR) with a Buy and maintains $5 price ta...

proqr-therapeutics-cash-and-cash-equivalents-and-short-term-financial-assets-of-1027m-as-of-end-of-q1-provides-runway-into-mid-2026
ProQR Therapeutics' Cash And Cash Equivale...
05/09/2024 11:58:46

proqr-therapeutics-q1-2024-gaap-eps-009-misses-007-estimate-sales-4450m-beat-3144m-estimate
ProQR Therapeutics Q1 2024 GAAP EPS €(0.09...
05/09/2024 11:56:56

proqr-gives-preclinical-proof-of-concept-data-for-ax-0810-axiomer-rna-editing-program-targeting-ntcp-for-cholestatic-diseases
ProQR Gives Preclinical Proof Of Concept D...
05/08/2024 12:27:33

ProQR scientists report for the first time in the ADAR RNA editing field in vivo proof of target engagement (RNA editing) leadi...

proqr-therapeutics-to-present-on-axiomer-rna-editing-at-asgct-27th-annual-meeting
ProQR Therapeutics To Present On Axiomer R...
04/22/2024 20:39:07

proqr-therapeutics-says-it-achieved-successful-defense-of-new-challenge-to-its-axiomer-ip-portfolio
ProQR Therapeutics Says It Achieved Succes...
04/19/2024 11:06:57

The company announced it has again successfully defended against opposition filed against a key patent for its ADAR-mediated RN...

hc-wainwright--co-reiterates-buy-on-proqr-therapeutics-maintains-5-price-target
HC Wainwright & Co. Reiterates Buy on ProQ...
03/14/2024 11:16:31

HC Wainwright & Co. analyst Andrew Fein reiterates ProQR Therapeutics (NASDAQ:PRQR) with a Buy and maintains $5 price ta...

chardan-capital-maintains-buy-on-proqr-therapeutics-raises-price-target-to-25
Chardan Capital Maintains Buy on ProQR The...
03/14/2024 10:27:32

Chardan Capital analyst Keay Nakae maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and raises the price target from $2...

proqr-therapeutics-2023-cash-and-cash-equivalents-of-1189m-is-expected-to-provide-cash-runway-into-mid-2026
ProQR Therapeutics' 2023 Cash And Cash Equ...
03/13/2024 11:10:36

proqr-therapeutics-fy-eps-038-up-from-097-yoy
ProQR Therapeutics FY EPS $(0.38) Up From ...
03/13/2024 11:09:21

ProQR Therapeutics (NASDAQ:PRQR) reported quarterly losses of $(0.38) per share. This is a 61.09 percent increase over losses o...

proqr-says-japanese-axiomer-patent-upheld-following-opposition-against-its-ip-estate-for-adar-mediated-rna-editing
ProQR Says Japanese Axiomer Patent Upheld ...
02/15/2024 12:20:34

proqr-therapeutics-highlights-new-platform-data-from-presentation-on-axiomer-rna-editing-technology-company-says-platform-demonstrates-robust-in-vivo-editing-capabilities-reporting-up-to-70-editing-of-actb-in-liver-of-non-human-primates-nhps-and-mice
ProQR Therapeutics Highlights New Platform...
01/19/2024 12:12:09

proqr-highlights-new-platform-data-from-presentation-on-axiomer-rna-editing-technology-at-deaminet-2024
ProQR Highlights New Platform Data from Pr...
01/19/2024 12:05:59

Platform demonstrates robust in vivo editing capabilities reporting up to 70% editing of ACTB in the liver of non-human prima...

why-keycorp-shares-are-trading-lower-by-over-5-here-are-other-stocks-moving-in-thursdays-mid-day-session
Why KeyCorp Shares Are Trading Lower By Ov...
01/18/2024 18:08:48

Shares of KeyCorp (NYSE: KEY) moved lower during Thursday’s session after the company reported fourth-quarter financial results...

why-airspan-networks-shares-are-trading-higher-by-over-380-here-are-other-stocks-moving-in-wednesdays-mid-day-session
Why Airspan Networks Shares Are Trading Hi...
01/17/2024 18:12:57

Shares of Airspan Networks Holdings Inc. (NASDAQ: MIMO) shares rose sharply during Wednesday’s session after the company announ...

proqr-therapeutics-and-rett-syndrome-research-trust-join-forces-with-axiomer-rna-editing-collaboration-for-development-of-therapies-for-central-nervous-system-diseases
ProQR Therapeutics And Rett Syndrome Resea...
01/05/2024 12:14:58

proqr-therapeutics-divested-its-ophthalmic-assets-sepofarsen-and-ultevursen-to-laboratoires-tha-for-an-initial-payment-of-8m-and-may-be-eligible-for-up-to-165m-in-milestone-payments
ProQR Therapeutics Divested Its Ophthalmic...
12/08/2023 12:33:04

us-stocks-lower-dow-falls-over-50-points
US Stocks Lower; Dow Falls Over 50 Points
11/27/2023 14:46:30

U.S. stocks traded lower this morning, with the Dow Jones index falling over 50 points on Monday. Following the market opening...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)
07/16/2024 Teladoc Health, Inc. (TDOC)
07/16/2024 Vestis Corporation (VSTS)
07/22/2024 Cambium Networks Corporation (CMBM)
07/22/2024 Biogen Inc. (BIIB)
07/23/2024 Fastly, Inc. (FSLY)
07/29/2024 Enphase Energy, Inc. (ENPH)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)